Partners Summit Therapeutics and Akeso are expected to steal the show at the American Society of Clinical Oncology’s annual ...

Analysts homed in on Duchenne muscular dystrophy and myotonic dystrophy type 1 assets during first quarter earnings as major ...

After getting slapped with a surprise refuse-to-file letter signed by former CBER Director Vinay Prasad, Moderna’s flu ...

Biogen and Denali’s Parkinson’s disease drug failed to significantly slow disease progression in a Phase 2b study, missing ...

While Biogen’s tau-targeting therapy didn’t demonstrate improvement on a dementia severity scale, the company touted ...

UCB’s Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie’s Skyrizi in a Phase 3 head-to-head study ...

Lilly met analysts’ sky-high expectations with 28.3% weight loss over 80 weeks for the triple hormone receptor agonist ...

Biotech’s antibody-drug conjugate significantly improved progression-free and overall survival in a pivotal endometrial ...

Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...

Aardvark Therapeutics had previously voluntarily suspended studies of ARD-101—and a related asset called ARD-201—after ...

Biotech is increasingly financed, governed and regulated as though it were a mature pharmaceutical industry rather than a ...

Far fewer companies are letting employees go so far in 2026 compared to 2025, but the number of people affected is trending ...